Get started

Investment

Cardano to road to $10 USDThis it's my next target profit in Cardano to hold by long term. These targets profits are my goal to hit in this bull rally. So, at the moment, I hold over 14,400 ADA coins. And also, during this rally, I want to accumulate Cardano to reach 17,000 ADA coins and then hold. Now, I thinking when Cardano reach $10 dollar. I want to sell 1,000 ADA x $10 dollar = $10,000 USD. It's to get $10,000 USD and use this money to buy Silver. Silver it's money and I like to invest in this metal, But Silver has future by long term and each targets for example: The next stop will be $23 USD, I repeat to sell 1,000 ADA x $23 USD to get $23,000 USD more late and use this money to re-buy more Silver. I do not buy Gold as you check out, Silver it's undervalued and Silver rally will start in the future as this kind of money take demand in based that world economy it's overall with this financial crisis where we live. But that it's my plan, and also Gold and Silver are good heavy assets that we should to buy. But another plan it's when I get $10,000 USD, it's invest $5k in Gold and $5k in Silver to diversify. The same I repeat when I sell my Cardano at $23 USD next target up. Now, Cadano it's so bullish and we believe that Cardano it's the best cryptocurrency that get a much adoption for the Blockchain technology. In minutes, i will going to update the another multitimeframes like weekly or Daily
BINANCE:ADAUSDLong
by harisonhbn9718
10
Xiaomi Expects to Invest Over CNY 13 Bn in R&D in 2021Xiaomi's official Weibo showed that the company's investment in technology research and development (R&D) had increased steadily over the past two years. On August 8, Xiaomi officially announced that its investment in R&D has increased at a compound annual growth rate of 30% in the past two years. In addition to wired and wireless fast charging, the company also has layout and output in chips. As early as February 2021, Lei Jun, Xiaomi's founder, revealed that the firm had invested CNY 10 billion in R&D in 2020. In 2021, Xiaomi will continue to maintain a high investment in R&D, which is expected to increase by 30% to 40% (about CNY 13 billion to CNY 14 billion). The financial report shows that in 2020, the company invested CNY 9.3 billion in R&D, with a year-on-year growth of 23.5%. In the first quarter of 2021, its R&D expenditure was CNY 3 billion, representing an increase of 61%. Although Xiaomi's R&D investment still lags behind some leading mobile phone manufacturers such as Apple, Huawei and Samsung, the firm's sales are impressive since 2021. The Canalys report shows that in Q2 2021, the global smartphone shipments were about 316 million units, with a month-on-month decrease of 9%. Among them, Xiaomi ranked second with shipments of 52.8 million units, showing a year-on-year growth of 83%. This is also the first time that the company ranked second in terms of shipments. On August 5, a report released by Counterpoint Research, a data research firm, showed that in June 2021, Xiaomi's global mobile phone market share rose to 17.1%, surpassing Samsung (15.7%) and Apple (14.3%), ranking first in the world. Meanwhile, its mobile phone sales grew by 26%, making it the fastest-growing brand for the month. For full articles with the charts, please visit the original link.
OTC:XIACF
by EqualOcean
$DOGE.X PT 15 and higher next$DOGE.X to the Moon SpaceX will basically mine Iridium Iridium is needed for EV batteries The average annual price for iridium in 2020 was 2,550 U.S. dollars per troy ounce. The price of iridium dramatically increased in March 2021, to 6,000 U.S. dollars per troy ounce as a result of supply shortages combined with its prospective use to produce green hydrogen. Iridium is a transition metal and a platinum group metal. It is one of the most corrosion-resistant metals and is also one of the rarest elements in the Earth's crust.
by BADQOMOCAWGOWLD
4
$VXRT entry Target PTs 7.20-8-8.20 Long term PTs 75-200-500$VXRT entry Target PTs 7.20-8-8.20 Long term PTs 75-200-500 and higher...timeline Sept 2022 Wyckoff Re-accumulation after decline Catalyst: Shares of Vaxart (Nasdaq: VXRT) rose on Monday after the biotech said the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for its oral Coronavirus vaccine. Why Vaxart Stock Surged Today The vaccine maker has a promising new construct for its experimental COVID-19 tablet. What happened Shares of Vaxart (Nasdaq: VXRT) rose on Monday after the biotech said the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for its oral coronavirus vaccine. As of 2:20 p.m. EDT, Vaxart's stock price was up more than 12%. So what Vaxart's S-only vaccine construct produced higher serum antibodies than its other vaccine candidate, which expresses both S and N proteins, in a non-human primate study. Vaxart plans to begin a phase II clinical trial for its S-only vaccine later this year. "This new clinical trial will allow us to compare the S-only and S+N vaccine candidates and put us in a position to decide which approach offers the best way forward for our COVID-19 vaccine development program, particularly in the face of emerging variant strains," Vaxart's chief scientific officer Dr. Sean Tucker said in a press release. Now what If Vaxart's new vaccine construct can produce a stronger antibody response in human patients than its other oral vaccine did in prior studies, it could become a more legitimate competitor to the COVID-19 drugs developed by Pfizer and Moderna. As a tablet, Vaxart's oral vaccine would be easier to store, transfer, and administer. If Vaxart can demonstrate a comparable efficacy and safety profile to the leading vaccines currently on the market, there would likely be tremendous demand for its new drug. This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
NASDAQ:VXRTLong
by BADQOMOCAWGOWLD
2
$CLDX PT 400 and higherCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
NASDAQ:CLDXLong
by BADQOMOCAWGOWLD